Solid Tumors, KRAS Mutation; SOS1 research hub

A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)

This study is for adults with advanced cancer that has a specific change called a KRAS mutation. It tests new doses of a medicine called BI 1701963, given alone or with another drug, trametinib. The goal is to find safe doses and see if they can shrink tumours.